Literature DB >> 12922129

Induction of cross-protection against two wild-type Taiwanese isolates of Japanese encephalitis virus using Beijing-1 strain DNA vaccine.

Chang-Jer Wu1, Hui-Wen Huang, Mi-Hua Tao.   

Abstract

Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, is an important human pathogen. Mouse brain-derived, inactivated JEV vaccines have contributed greatly to the reduction in numbers of JE patients in several countries, including Taiwan. However, mice immunized with the Nakayama strain inactivated vaccine show lower protection against a lethal strain of Beijing-1 JEV than those immunized with the homologous vaccine. DNA vaccine encoding the envelope (E) protein gene appears to provide protection against JEV in the mouse model, but it is not known whether such vaccines would confer cross-protection for mice against different strains of JEV. In this study, we evaluated the ability of pE, a plasmid DNA vaccine encoding the Beijing-1 envelope protein to elicit cross-protective immunity against infection with the homologous Beijing-1 strain and two lethal Taiwanese isolates of JEV, CH2195 and CEN. Our results showed that mice immunized with pE were protected against lethal challenge with Beijing-1 JEV as well as two Taiwanese isolates. In addition, nai;ve mice were cross-protected by passive transfer of sera from immunized animals, indicating the crucial role of humoral immunity in protection. These results demonstrate that JEV DNA vaccine can provide effective protection against infection not only with homologous virus, but also with heterologous virus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12922129     DOI: 10.1016/s0264-410x(03)00277-9

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  1 in total

1.  Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.

Authors:  Ran Wang; Lyu Xie; Na Gao; Dongying Fan; Hui Chen; Peigang Wang; Hongning Zhou; Jing An
Journal:  Virol Sin       Date:  2019-03-25       Impact factor: 4.327

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.